title: Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
abstract: A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26). The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin (n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count >/=500/microl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count >/=20 000/microl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression n=8). FM patients had better overall survival (73 vs 39% at 18 months; P=0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival.
authors.affiliation: Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. panderli@mdanderson.org
authors.forename: P
authors.initials: P
authors.lastname: Anderlini
authors.forename: R
authors.initials: R
authors.lastname: Saliba
authors.forename: S
authors.initials: S
authors.lastname: Acholonu
authors.forename: G-J
authors.initials: GJ
authors.lastname: Okoroji
authors.forename: M
authors.initials: M
authors.lastname: Donato
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: B
authors.initials: B
authors.lastname: Andersson
authors.forename: N T
authors.initials: NT
authors.lastname: Ueno
authors.forename: I
authors.initials: I
authors.lastname: Khouri
authors.forename: M
authors.initials: M
authors.lastname: De Lima
authors.forename: C
authors.initials: C
authors.lastname: Hosing
authors.forename: A
authors.initials: A
authors.lastname: Cohen
authors.forename: C
authors.initials: C
authors.lastname: Ippoliti
authors.forename: J
authors.initials: J
authors.lastname: Romaguera
authors.forename: M A
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: B
authors.initials: B
authors.lastname: Pro
authors.forename: L
authors.initials: L
authors.lastname: Fayad
authors.forename: A
authors.initials: A
authors.lastname: Goy
authors.forename: A
authors.initials: A
authors.lastname: Younes
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D017708:Leukocyte Transfusion; D008297:Male; D008875:Middle Aged; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous